Preferred Label : Anti-CLDN18.2/Anti-PD-L1 CAR-T Cells;
NCIt synonyms : Anti-PD-L1/Anti-CLDN18.2 CAR-T Cells; Dual-targeting CLDN18.2 and PD-L1 CAR-T Cells; Anti-CLDN18.2/Anti-PD-L1 CAR T-cells; CLDN18.2/PD-L1-targeting CAR T Cells;
NCIt definition : A preparation of T-lymphocytes that have been genetically modified to express chimeric
antigen receptors (CARs) targeting the tumor-associated antigen (TAA) Claudin18.2
(CLDN18.2; A2 isoform of claudin-18) and the immunosuppressive ligand programmed cell
death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating
and antineoplastic activities. Upon administration, anti-CLDN18.2/anti-PD-L1 CAR-T
cells target and bind to CLDN18.2- and PD-L1-expressing tumor cells, thereby inducing
selective toxicity in CLDN18.2- and PD-L1-expressing tumor cells. CLDN18.2, a tight
junction protein and stomach-specific isoform of claudin-18, is expressed on a variety
of tumor cells, but its expression in healthy tissues is strictly confined to short-lived
differentiated epithelial cells of the gastric mucosa. PD-L1, which is overexpressed
in many human cancer cell types, plays an important role in the downregulation of
the immune system and tumor evasion from host immunity.;
Origin ID : C202229;
concept_is_in_subset
- has_target
